Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03652441
Title Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Cologne
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.